Search

Oudemansiella raphanipes (O. raphanipes) has recently been gaining popularity due to its active and flavor compounds. In this study, the profiles of phenolics, flavonoids, non-volatile and volatile compounds of fresh O. raphanipes were subjected to cutting root (CR) and pulling root (PR) harvesting methods during different storage temperatures (5 °C and 20 °C) were investigated. The results showed that CR treatment effectively increased phenolic and flavonoid contents, maintained the sensory scores and the umami value based on e-tongue, increased more C8 volatile contents, and inhibited off-flavor acids production during 5 °C storage. The EUC values of the fresh O. raphanipes ranged from 4.72 to 23.66 g monosodium glutamate (MSG) 100 g−1, which TAVs were at a relatively high level in CR treatment than in PR treatment. A two-way analysis of variance (ANOVA) and principal component analysis (PCA) revealed statistically significant differences in different harvesting methods that affected the mushroom flavor. Eleven components were screened as taste characteristics contributors by partial least squares regression model (PLS-R) analysis, including Glu, umami nucleotides, and 1-octene-3-ol and 3-octanone. Thus, the cutting root treatment is a promising method for obtaining the high flavor quality of fresh O. raphanipes during cooling storage. • The taste components of O. raphanipes were examined for the first time. • 11 components were mainly responsible for the O. raphanipes flavor. • Cutting root treatment increased umami compounds contents during 5 °C storage. • Cutting root treatment maintained more C8 volatile contents during 5 °C storage. • Cutting root treatment enhanced more active contents during 5 °C storage. [ABSTRACT FROM AUTHOR]

Myocardial dysfunction is a prevalent complication of sepsis (septic cardiomyopathy) with a high mortality rate and limited therapeutic options. Naringenin, a natural flavonoid compound with anti-inflammatory and antioxidant properties, holds promise as a potential treatment for sepsis-induced myocardial dysfunction. This study investigated the pharmacological effects of naringenin on septic cardiomyopathy. In vivo and in vitro experiments demonstrated that naringenin improved cardiomyocyte damage. Network pharmacology and database analysis revealed that HIF-1α is a key target protein of naringenin. Elevated expression of HIF-1α was observed in damaged cardiomyocytes, and the HIF-1α inhibitor effectively protected against LPS-induced cardiomyocyte damage. Molecular docking studies confirmed the direct binding between naringenin and HIF-1α protein. Importantly, our findings demonstrated that naringenin did not provide additional attenuation of cardiomyocyte injury on the biases of HIF-1α inhibitor treatment. In conclusion, this study proves that naringenin protects against septic cardiomyopathy through HIF-1α signaling. Naringenin is a promising therapeutic candidate for treating septic cardiomyopathy. • Naringenin protects against septic cardiomyopathy and improve cardiac health. • Molecular docking reveals naringenin's direct interaction with HIF-1α. • Naringenin is a promising therapeutic candidate for septic cardiomyopathy. [ABSTRACT FROM AUTHOR]